Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Technical Presentation (September 2021)

24 slides from Centessa Pharmaceuticals's technical presentation, Sep 9, 2021

  1. Slide 1: SerpinPC Phase 2a Results

    SEPTEMBER 9, 2021 SerpinPC Phase 2a Results

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Refo

  3. Slide 3: Today's Speakers

    SerpinPC Phase 2a Results 3 TODAY’S SPEAKERS GREG WEINHOFF MD MBA Chief Financial Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc Chief Medical Officer ADDITIONALLY AVAILABLE FOR Q&A TREVOR BAGLIN MedScD PhD Co-founder & Chief Medical Officer of ApcinteX

  4. Slide 4: Mission

    4 Mission Deliver consequential medicines to patients by striving to make the unprecedented possible

  5. Slide 5: Centessa at a glance

    Centessa at a glance Pipeline 5 1. Publications by members of the Centessa team Wholly-owned Companies10 Disclosed Programs16 Active Patents300 Rare Disease Assets 14 Subject-matter Experts20+ Oncology Assets6 Published Papers11000+ Assets in the Clinic4

  6. Slide 6: Diverse portfolio includes programs across multiple therapeutic areas

    Our diverse portfolio includes 16 programs across multiple therapeutic areas Pipeline 6 Clinical-stage companies A1AT Folding Corrector (Lead) Capella BioScience Anti-LIGHT mAbIdiopathic Pulmonary Fibrosis Anti-BDCA-2 mAbSystemic Sclerosis and Lupus Erythematosus LockBody Therapeutics Solid Tumors C

  7. Slide 7: Significant momentum with 2021 accomplishments

    Significant momentum with 2021 accomplishments Milestones 7 JANUARY 2021 • Launch • Acquisition of 10 biotech companies • $250M Series A MAY 2021 • Upsized $380M IPO SEPTEMBER 2021 Today’s focus • Proof of Concept Ph2a topline data for ApcinteX’s SerpinPC

  8. Slide 8: SerpinPC: first-in-class coagulation rebalancing agent for hemophilia

    8 Designed to be a first- in-class coagulation rebalancing agent for the treatment of hemophilia A and B SerpinPC

  9. Slide 9: Successful proof-of-concept results

    Successful proof-of-concept results Summary 9 The goals of this Phase 2a clinical proof-of-concept study were to evaluate the safety and efficacy of once monthly, subcutaneous SerpinPC in a population of hemophilia A and B patients not on prophylaxis and with a history of substantial bleeding We obs

  10. Slide 10: Unique MoA, supported by human genetics

    Unique MoA, supported by human genetics Mechanism of action 10 Amino acid modifications make SerpinPC a highly specific inhibitor of activated protein C Serpin: alpha-1-antitrypsin SerpinPC Extrinsic Tenase Intrinsic Tenase Prothrombinase Prothrombin Thrombin SerpinPC APC Protein C Feedback Loop

  11. Slide 11: Potential benefits of SerpinPC

    Potential benefits of SerpinPC Differentiation 11 Novel MoA for hemophilia A and B Excellent safety profile without potential thrombosis Convenient subcutaneous administration Compelling efficacy

  12. Slide 12: Phase 1/2a proof of concept study

    Phase 1/2a proof of concept study Overview of AP-0101 12 P H A S E 1 , H E A L T H Y V O L U N T E E R S P H A S E 1 , P E R S O N S W I T H H E M O P H I L I A P H A S E 2 a O N G O I N G O P E N - L A B E L E X T E N S I O N Objectives Patient population and study overview Evaluate safety, tolerab

  13. Slide 13: Positive proof of concept data from Phase 2a

    Positive proof of concept data from Phase 2a 13 SerpinPC was observed to be well-tolerated with no evidence of thrombotic risk At highest dose of 1.2 mg/kg SC once monthly: • All bleed ABR: Median 88% reduction • Spontaneous joint bleed ABR: Median 94% reduction • Zero target joints* at end of treat

  14. Slide 14: Clinical trial design and exploratory efficacy analyses

    Clinical trial design and exploratory efficacy analyses 14 Dosing and measurement every 4 weeks Baseline measurement Screening for 11 new subjects 12 subjects from Phase 1, PwH M I N . 8 W E E K O B S E R V A T I O N Weeks -26 to -2 Screening 2 Weeks -2 to Day -1 Assignment to one of three dose leve

  15. Slide 15: Endpoints, subjects and inclusion criteria

    Endpoints, subjects and inclusion criteria 15 ENDPOINTS Primary endpoint: Safety and tolerability Secondary endpoint: PK Exploratory endpoint: Reduction in ABR SUBJECTS PwH in Georgia and Moldova23 Hemophilia A without inhibitors19 Hemophilia B without inhibitors4 ABR of 6 or more during the observa

  16. Slide 16: Demographics and baseline characteristics

    Demographics and baseline characteristics 16 CHARACTERISTIC PHASE 2a (n=23) Age, median (min-max) 39 years (21-56 years) Male, % 100% Hemophilia A, % 83% (n=19) Hemophilia B, % 17% (n=4) Baseline ABR*, median total bleeds 35.5 Target joints**, % 100% Target joints, median 2.5 * Annualized rate of se

  17. Slide 17: SerpinPC well tolerated, no evidence of thrombotic risk

    SerpinPC was well tolerated, with no evidence of thrombotic risk 17 • No thrombosis • No instances of sustained elevations in D-dimer • 1 moderate skin reaction that led to withdrawal of a patient with a history of a skin disorder • 2 patients with ADAs, with no apparent impact on ABRs • No other Se

  18. Slide 18: Median 88% reduction in ABR for all bleeds at 1.2 mg/kg

    Median 88% reduction in ABR for all bleeds at 1.2 mg/kg 18 CHANGE IN ABR (%) 0.3 mg/kg 0.6 mg/kg n=8 p=0.016 n=7 p=0.016 n=7 p=0.031 -88% -70% -100% -80% -60% -40% -20% 0% 20% 40% -80% 1.2 mg/kg At highest dose of 1.2 mg/kg, median all bleeds ABR reduced from 36.0 to 4.4

  19. Slide 19: Median 94% reduction in ABR for spontaneous joint bleeds

    Median 94% reduction in ABR for spontaneous joint bleeds at 1.2 mg/kg 19 CHANGE IN ABR (%) 0.3 mg/kg 0.6 mg/kg n=8 p=0.023 n=7 p=0.016 n=7 p=0.031 1.2 mg/kg -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% -94% -69% -76% At highest dose of 1.2 mg/kg, median spontaneous joint bleeds ABR reduced from 21.1

  20. Slide 20: Reduction in median target joints at all dose levels

    Observed reduction in median target joints from 2.5 to 0 at all dose levels 20 TARGET JOINTS* (NUMBER) Start of treatment period End of treatment period All dose levels n=22 * Target joint = joint with >3 bleeds in any 6-month period All dose levels n=22 p<0.0001 0 1 2 3 4 5 Max 3rd quartile Median

  21. Slide 21: Similar ABR reduction in hemophilia A and B

    Similar reduction in ABR for all bleeds observed in hemophilia A and hemophilia B 21 Median change in all bleeds ABR 0.3 mg/kg 0.6 mg/kg 1.2 mg/kg Hemophilia A -80% (n=5) -64% (n=5) -88% (n=8) Hemophilia B -72% (n=2) -73% (n=2) No subjects * Post hoc analysis, no p-values calculated

  22. Slide 22: Potential benefits of SerpinPC

    Novel MoA for hemophilia A and B Excellent safety profile without potential thrombosis Potential benefits of SerpinPC 22 Compelling efficacy Convenient subcutaneous administration

  23. Slide 23: Path forward

    23 Following our positive readout in hemophilia A and B, we will pursue a global full development plan aimed at one or more registrations PATH FORWARD

  24. Slide 24: Thank you

    24 Thank you Thank you to all patients who participated in this trial and to the clinical study team

Centessa Pharmaceuticals — Technical Presentation (September 2021) on 6ix